Prevalence and factors associated with renal impairment in HIV‐infected patients, ANRS C03 Aquitaine Cohort, France

Prevalence and factors associated with renal impairment in HIV‐infected patients, ANRS C03 Aquitaine Cohort, France

Objectives The aims of the present study were to estimate the prevalence of renal impairment (RI) among HIV‐infected adult patients and to investigate the associated factors. Methods A cross‐sectional survey was conducted in a French hospital‐based cohort. Clearance of creatinine (CC) was calculated...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:HIV medicine 2010-05, Vol.11 (5), p.308-317
Hauptverfasser: Déti, EK, Thiébaut, R, Bonnet, F, Lawson‐Ayayi, S, Dupon, M, Neau, D, Pellegrin, JL, Malvy, D, Tchamgoué, S, Dabis, F, Morlat, P
Format: Artikel
Sprache:eng
Schlagworte:
Adenine - adverse effects
Adenine - analogs & derivatives
Adult
Age
Anti-HIV Agents - adverse effects
Body Mass Index
CD4 antigen
CD4 Lymphocyte Count
Creatinine
Creatinine - blood
Epidemiologic Methods
Female
France - epidemiology
HIV infection
HIV Infections - complications
HIV Infections - drug therapy
HIV Infections - epidemiology
Human immunodeficiency virus
Humans
Hypertension
Hypertension - epidemiology
Indinavir
Indinavir - adverse effects
kidney
Kidney - drug effects
Kidney Function Tests
Male
Middle Aged
Organophosphonates - adverse effects
Regression analysis
Renal function
renal impairment
Renal Insufficiency - epidemiology
Renal Insufficiency - etiology
Tenofovir
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Objectives The aims of the present study were to estimate the prevalence of renal impairment (RI) among HIV‐infected adult patients and to investigate the associated factors. Methods A cross‐sectional survey was conducted in a French hospital‐based cohort. Clearance of creatinine (CC) was calculated using the Cockcroft–Gault formula. Four stages of RI were defined: mild (60–90 mL/min), moderate (30–60), severe (15–30) and end stage (
ISSN:1464-2662
1468-1293
DOI:10.1111/j.1468-1293.2009.00780.x